A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

Authors :: Sardnal, V
Rouquette, A
Kaltenbach, S
Bally, C
Chesnais, V
Leschi, C
Ades, L
Santini, V
Park, S
Toma, A
Fenaux, P
Dreyfus, F
Fontenay, M
Kosmider, O
Source :: Leukemia (08876924); Jul2013, Vol. 27 Issue 7, p1610-1613, 4p, 1 Chart
Publication Year :: 2013
Abstract: The article presents a study which shows the role of A/G polymorphism in the E3 ubiquitin ligase protein Cereblon (CRBN) gene as biomarker of response to treatment with lenalidomide. It notes that 66 patients with myelodysplastic syndromes (MDS) received lenalidomide for 21 days and the role of CRBN gene in the response to lenalidomide was investigated in the study. Furthermore, the study determined that CRBN expression level does not seem to be involved in lenalidomide in low/int-1 MDS.

Subjects :: MYELODYSPLASTIC syndromes
BIOMARKERS
UBIQUITIN ligases
GENE expression
GENETIC polymorphisms

Full Text Access

Tools